Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Honig

Showing results (231-240 of 273) with videos related to

Pageof 28
Sort By:
Acta Neuropathologica|June 3, 2025
Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer diseaseCharles D Chen, Erin E Franklin, Yan Li, et al.
Frontiers in Neurology|February 17, 2022
Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA SymposiumGregory D Scott, Moriah R Arnold, Thomas G Beach, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2025
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trialAustin McCullough, Charles D Chen, Brian A Gordon, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 10, 2023
Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS)Hanna Cho, Nidhi S Mundada, Liana G Apostolova, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 5, 2023
Longitudinal head-to-head comparison of <sup>11</sup>C-PiB and <sup>18</sup>F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's diseaseCharles D Chen, Austin McCullough, Brian Gordon, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 27, 2023
Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's diseaseSára Nemes, Paige E Logan, Mohit K Manchella, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 9, 2023
Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohortAngelina J Polsinelli, Ryan J Wonderlin, Dustin B Hammers, et al.
JMIR Aging|June 26, 2024
Examining Associations Between Smartphone Use and Clinical Severity in Frontotemporal Dementia: Proof-of-Concept StudyEmily W Paolillo, Kaitlin B Casaletto, Annie L Clark, et al.
JAMA Neurology|April 17, 2013
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodiesMichael A Nalls, Raquel Duran, Grisel Lopez, et al.
Annals of Neurology|September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
Pageof 28

Showing results (231-240 of 273) with videos related to

Sort By:
Pageof 28
Acta Neuropathologica|June 3, 2025
Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer diseaseCharles D Chen, Erin E Franklin, Yan Li, et al.
Frontiers in Neurology|February 17, 2022
Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA SymposiumGregory D Scott, Moriah R Arnold, Thomas G Beach, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 15, 2025
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN-TU-001 trialAustin McCullough, Charles D Chen, Brian A Gordon, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 10, 2023
Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS)Hanna Cho, Nidhi S Mundada, Liana G Apostolova, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 5, 2023
Longitudinal head-to-head comparison of <sup>11</sup>C-PiB and <sup>18</sup>F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's diseaseCharles D Chen, Austin McCullough, Brian Gordon, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 27, 2023
Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's diseaseSára Nemes, Paige E Logan, Mohit K Manchella, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 9, 2023
Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohortAngelina J Polsinelli, Ryan J Wonderlin, Dustin B Hammers, et al.
JMIR Aging|June 26, 2024
Examining Associations Between Smartphone Use and Clinical Severity in Frontotemporal Dementia: Proof-of-Concept StudyEmily W Paolillo, Kaitlin B Casaletto, Annie L Clark, et al.
JAMA Neurology|April 17, 2013
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodiesMichael A Nalls, Raquel Duran, Grisel Lopez, et al.
Annals of Neurology|September 24, 2022
Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer DiseaseNelly Joseph-Mathurin, Jorge J Llibre-Guerra, Yan Li, et al.
Pageof 28